Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.64 |
| ▸ | SLC9A2 | Q9UBY0 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6312203 | 0.99 | SLC9A1 (0.62) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6261708 | 0.84 | HTR2C (0.53) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312201 | 0.83 | SLC9A1 (0.45) | SLC9A1HTR2CMALT1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6313406 | 0.83 | HTR2C (0.53) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312790 | 0.81 | SLC9A1 (0.44) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6312192 | 0.80 | SLC9A1 (0.43) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL3713540 | 0.80 | SLC9A1 (0.60) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6261873 | 0.79 | HTR2C (0.42) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6314064 | 0.79 | SLC9A1 (0.59) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6313991 | 0.78 | HTR2C (0.42) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-2015189236-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-12-17 | — | — | WO | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-2005079803-A1 | COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES | PFIZER PRODUCTS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | disclosed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885OPRM1 2426/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | SLC9A1 2/4885SLC9A2 13/4885OPRM1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.